Navigation Links
Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2013
Date:7/24/2013

ash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q, its most recently filed reports on Form 8-K, and its most recently filed Annual Report on Form 10-K, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

 [Financial tables follow]SEQUENOM, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)(In thousands, except per share information) Three Months EndedJune 30, Six Months EndedJune 30,2013201220132012Revenues:Diagnostic services

$   24,526$
8,110$53,609$12,890Genetic analysis product sales and services

10,32510,14219,74020,282Total revenues

34,85118,25273,34933,172Cost of revenues:Cost of diagnostic services

20,6349,40741,71316,278Cost of genetic analysis product sales and services

3,6993,6987,1587,121Total cost of revenues

24,33313,10548,87123,399Gross margin

10,5185,14724,4789,773Operating expenses:Selling and marketing

13,45211,31027,10920,987Research and development

13,01913,07026,85324,914General and administrative

12,7359,94926,21817,299Total operatin
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sequenom, Inc. Announces Issuance Of Patent For Methods Of Detecting Fetal Aneuploidy
2. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
3. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
4. Cepheid Reports 2013 Second Quarter Results
5. Quest Diagnostics Reports Second Quarter 2013 Financial Results
6. Global GIS Market in the Retail Industry to 2016: Industry Analysis, Growth, Strategy, Size, Shares, Trend and Forecast Research Report Available at MarketResearchReports
7. Comprehensive Topical Reports by Transparency Market Research Now Available at MarketPublishers.com
8. NREL reports 31.1 percent efficiency for III-V solar cell
9. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
10. DNA Sequencing Market 2013 Developments & 2016 Product Forecasts in New Research Reports at ReportsnReports.com
11. Z Trim Holdings Reports Continued Sales Growth in May 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Commercialization of the Revolutionary ... Accuri C6 Flow Cytometer(R) System--, ... a life,sciences company developing revolutionary bench-top flow cytometer systems,today ... financing led by,Fidelity Biosciences and Flagship Ventures. Current investors ...
... 8 Concentric Pharma Advertising, Inc., a,five-year-old ... growing in the,field, has been selected by ... a developmental once-daily,medication for the treatment of ... include a broad range of activities,including branding, ...
... 7 American Oriental,Bioengineering, Inc. (NYSE: AOB ... market conditions and other factors, $85 million aggregate,principal ... qualified,institutional buyers in a private placement exempt from ... as amended (the "Securities,Act")., AOB currently expects ...
Cached Biology Technology:Accuri Cytometers Completes $13 Million Series C Financing 2Accuri Cytometers Completes $13 Million Series C Financing 3Accuri Cytometers Completes $13 Million Series C Financing 4Concentric Wins Full-Service Professional Assignment From Biopharm Innovator Neuromed 2American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes 2American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes 3
(Date:4/23/2014)... The trope that the likelihood of an accurate group ... not hold up when a collective faces a variety ... nature. Instead, Princeton University researchers report that smaller groups ... assemblies may become excessively focused on only certain pieces ... to what is known about collective intelligence, or the ...
(Date:4/23/2014)... turning away from using triclosan as an antimicrobial ingredient ... And now scientists are reporting new evidence that appears ... ACS journal Chemical Research in Toxicology , found ... octylphenol, promoted the growth of human breast cancer cells ... , Kyung-Chul Choi and colleagues note that hormonal imbalances ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... This press release is available in French ... and men contribute equally to the lineage of contemporary populations? ... polygamy or monogamy? To answer these questions, Dr. Damian Labuda, ... a professor at the Department of Pediatrics of the Universit ...
... professor of chemistry at New Jersey Institute of ... patent today for a novel composition of matter. ... (US Patent Number 7,670,684) discloses a new self-contained ... comprised of organic scaffolds with metal centers, which ...
... worldwide. It is the most common form of age-related dementia, ... no cure, and the available drugs only help to relieve ... characteristic changes in the brains of Alzheimer,s patients is the ... curing or at least slowing the disease lies in developing ...
Cached Biology News:Modern man found to be generally monogamous, moderately polygamous 2NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating 2The sea squirt offers hope for Alzheimer's sufferers 2
Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
... cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide White solid. ... A potent inhibitor of MMP-2 that acts ... = 1.7 μM). Purity: ≥98% by ... Unstable in solution, reconstitute just prior to ...
MAb to Vasopressin Preservative: NaN3...
Biology Products: